Search Clinical Trials in the European Union

Duration
11-15 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
141-160 of 306 trials

Peyronie's Disease: Study of Bacterial Collagenase

We are testing a new bacterial collagenase injection for men with Peyronie's Disease to see if it improves penile curvature and reduces discomfort. The study will assess both safety and effectiveness of this treatment.

Peyronie's Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesUrology

Localized Prostate Cancer: Darolutamide and Radiation Therapy

We are studying the effects of darolutamide with or without radiation therapy in patients with localized prostate cancer at high risk of relapse. The goal is to see if this combination improves survival and quality of life.

Localized Prostate Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Metastatic Non-Small Cell Lung Cancer: Zimberelimab and Domvanalimab Study

We are comparing a new treatment combination with chemotherapy to standard treatment for patients with untreated metastatic non-small cell lung cancer. This study aims to see which option may help improve survival and response rates.

Metastatic Non–Small Cell Lung CancerConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced Cancers: BI-1808 Monoclonal Antibody

We are studying a new treatment called BI-1808 for people with advanced cancers, both alone and with pembrolizumab. The goal is to assess its safety and how well it is tolerated by patients.

Malignant Solid Tumor>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Pegozafermin for Metabolic Dysfunction-Associated Steatohepatitis (MASH)

We are studying whether pegozafermin can improve liver health in people with MASH and fibrosis compared to a placebo. This trial will help us understand its safety and effectiveness over time.

Nonalcoholic Fatty Liver Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyHepatology

Mucopolysaccharidosis IIIA: Gene Therapy Study

We are testing a new gene therapy called UX111 for individuals with Mucopolysaccharidosis IIIA. The goal is to see if it is safe and effective in treating this condition.

Mucopolysaccharidosis III>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurologyPediatrics

Cerebral Amyloid Angiopathy: ALN-APP Treatment Study

We are studying a new treatment called ALN-APP for patients with Cerebral Amyloid Angiopathy. The goal is to see if it helps reduce new brain bleeding and improve overall brain health.

Cerebral Amyloid Angiopathy1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Chronic Lymphocytic Leukemia: Venetoclax and Pirtobrutinib Study

We are comparing different treatment plans for newly diagnosed chronic lymphocytic leukemia patients to see if a personalized approach improves outcomes. This includes assessing how long patients can stay in remission and the overall effectiveness of the treatments.

Chronic Lymphocytic Leukaemia (CLL)Small Lymphocytic Lymphoma (SLL)>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Head and Neck Cancer: Petosemtamab Treatment Study

We are studying the effects of petosemtamab in patients with advanced head and neck cancer who have not responded to previous treatments. The goal is to see if it improves survival and tumor response compared to standard therapies.

Metastatic Head and Neck Squamous Cell Carcinoma>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Paroxysmal Nocturnal Hemoglobinuria: Pozelimab and Cemdisiran Therapy

We are studying the long-term safety and effectiveness of a combination therapy for adults with Paroxysmal Nocturnal Hemoglobinuria. This trial will help us understand its impact on symptoms like fatigue and hemoglobin levels.

Paroxysmal Nocturnal Hemoglobinuria>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Cirrhosis Treatment: Pegozafermin Study

We are studying a new medication, pegozafermin, for individuals with compensated cirrhosis due to MASH. The goal is to see if it can improve liver health and reduce related health risks compared to a placebo.

Chronic Liver Disease and Cirrhosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyHepatology

Crohn's Disease: AZD7798 Treatment Study

We are investigating how well AZD7798 works and its safety for people with moderate to severe Crohn's disease. This study will help us understand its effects on disease activity and overall health.

Crohn's Disease1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

HIV Prevention: Long-Acting Injectable Cabotegravir vs. Daily Oral Medication

We are studying whether a long-acting injectable form of cabotegravir is more effective than daily oral medication for preventing HIV in men who have sex with men. This trial aims to understand how well each option works over time and their impact on participants' health and behaviors.

HIV Prevention>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesInternal Medicine

Breast Cancer: Fezolinetant for Hot Flashes

We are studying whether fezolinetant can help reduce hot flashes in women with hormone receptor-positive breast cancer receiving hormone therapy. The trial also looks at how this treatment affects quality of life and sleep.

Hot Flashes1-2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteEndocrinologyOncology

Glioblastoma Treatment: Olaptesed Pegol with Radiation

We are studying the safety and effectiveness of olaptesed pegol combined with radiation therapy for patients with newly diagnosed glioblastoma and unmethylated MGMT promoter. This trial also explores how different doses may impact treatment outcomes.

Glioblastoma6-12 monthsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Diffuse Large B-Cell Lymphoma: Epcoritamab Plus Lenalidomide

We are studying whether a new combination of epcoritamab and lenalidomide can improve survival rates for adults with relapsed or refractory diffuse large B-cell lymphoma compared to standard treatments.

Relapsed or Refractory Diffuse Large B-Cell Lymphoma6-12 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Acute Myeloid Leukemia: Venetoclax and Azacitidine with Cusatuzumab

We are studying whether adding cusatuzumab to standard treatment helps newly diagnosed AML patients who can't have intensive therapy. This trial will also look at the safety and effectiveness of this combination.

Acute Myeloid LeukemiaEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Cystic Fibrosis: SPL84 Inhalation Treatment

We are testing a new inhaled medication, SPL84, for patients with cystic fibrosis to see if it is safe and how well it works. This study will help us understand its effects on this specific group of patients.

Cystic Fibrosis3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesInternal MedicinePulmonology

Epithelial Ovarian Cancer: Letrozole Maintenance Therapy

We are studying whether letrozole can help women with epithelial ovarian cancer stay cancer-free after surgery and chemotherapy. This trial compares letrozole to a placebo to see if it improves outcomes.

Ovarian Epithelial CancerConfirmation phase (III)11-15 visitsInvestigational MedicinesGynecology and ObstetricsOncology

Atopic Dermatitis: APG777 Treatment Study

We are studying a new treatment called APG777 for people with moderate-to-severe atopic dermatitis. The goal is to see if it helps reduce symptoms like itching and skin pain compared to a placebo.

Atopic Dermatitis>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology